KERICURE INC. — Department of Defense SBIR Phase II: DHA SEQUENTIAL PHASE II SBIR DEPLOYABLE WOUND CARE PRODUCTS TO DECREASE PREVENTABLE DEATH
KERICURE INC. — SBIR Phase II award from Department of Defense.
Phase II SBIR prototype / development signal
- Phase II is where Department of Defense funds deeper R&D after feasibility. Incumbents with Phase II history are serious competitors on adjacent topics.
- Use this award as past-performance context and to map customer organizations for STRATFI/TACFI-style transition planning.
- Obligated amount $1,299,857 is consistent with substantial Phase II-scale effort; compare to related awards from the same agency.
- Tagged technology areas: Human Performance & Medical. Follow those hubs for open topics and peer winners in the same cluster.
Summary
Kericure Inc. received over $1.2 million from the Department of Defense to develop portable wound care products. These products aim to reduce preventable deaths by preventing infections in battlefield injuries and during extended medical care.
- Amount
- $1,299,857
- Agency
- Department of Defense · Defense Health Agency
- Program / Phase
- SBIR · Phase II
- NAICS
- 541715 · RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
- Place of performance
- FL
- Period
- 2023-09-22 → 2027-04-21
Technology domains
Description
DHA SEQUENTIAL PHASE II SBIR DEPLOYABLE WOUND CARE PRODUCTS TO DECREASE PREVENTABLE DEATH OUTCOMES BY MITIGATING INFECTION ON BATTLEFIELD AND THROUGH LONG TERM CARE